Eligibility criteria
Condition
Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
Sex
Females and Males
Age
0-2
Inclusion criteria
Show details
- Subject is an infant born to a mother who was exposed to study drug on a tanezumab
clinical study.
- The infant's mother (who was the tanezumab clinical study participant) must review,
agree and sign an informed consent document explaining the details of the perinatal
and post natal follow up. Where local regulations mandate, the male parent would also
review and sign the informed consent.
- Parents or legal guardian must be willing and able to comply with scheduled visits and
study procedures.
Exclusion criteria
Show details
- There are no exclusion criteria for participating in this study.